Hem-Onc News: Aspirin linked to cancer progression in older adults

Tuesday, September 1, 2020

MDedge Hematology-Oncology news for the first week of September 2020.

  1. Aspirin may accelerate cancer progression in older adults: https://bit.ly/2ENHRUc
    ASPREE trial: https://bit.ly/2QAsMYW
    Meta-analysis: https://bit.ly/2D6rXnl
    AsCaP: https://bit.ly/2G06X2I
  2. Black/White gap gone: ‘The only cancer where this has happened’: https://bit.ly/3jm8PBm
    Source: https://bit.ly/3lv4u0m
  3. Selpercatinib 'poised to alter the landscape' of RET+ cancers: https://bit.ly/34PYSbs
    Lung cancer results: https://bit.ly/3gB1FY7
    Thyroid cancer results: https://bit.ly/2EHhCz5
  4. Study confirms it's possible to get COVID-19 twice: https://bit.ly/3bd4wWg

Email the show: podcasts@mdedge.com

Learn more about MDedge and Blood & Cancer: https://www.mdedge.com/podcasts

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.